drugset / Trial / NCT05707351
A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A
NaSingle-groupOpen-labelTreatment
Summary
The main aim of the study is to determine how well Adynovate works to decrease bleeding in previously treated Chinese men and boys with severe hemophilia A when given prophylactically. Participants will be treated with Adynovate twice a week for 26 weeks or until participants have received 50 days of treatment with Adynovate (whichever takes longer). Participants will need to visit their study clinic several times during their participation.
Timeline
- Start
- 2023-03-27
- Primary completion
- 2024-09-05
- Completion
- 2024-09-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ANTIHEMOPHILIC FACTOR, PEGYLATED (MW 20000) HUMAN SEQUENCE RECOMBINANT | Protein / enzyme biologic | 45 iu/kg | Intravenous |